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Abstract
Background: Tissue plasminogen activator (tPA) exerts multiple functions in the central nervous system,
depending on the partner with which it interacts. In particular, tPA acts as a positive neuromodulator of N-methyl-
D-aspartate glutamatergic receptors (NMDAR). At the molecular level, it has been proposed that the pro-
neurotoxicity mediated by tPA might occur through extrasynaptic NMDAR containing the GluN2D subunit. Thus,
selective antagonists targeting tPA/GluN2D-containing NMDAR signaling would be of interest to prevent noxious
effects of tPA.
Results: Here, we compared three putative antagonists of GluN2D-containing NMDAR and we showed that the
new compound UBP145 ((2R*,3S*)-1-(9-bromophenan-threne-3-carbonyl)piperazine-2,3-dicarboxylic acid) is far more
selective for GluN2D subunits than memantine and PPDA (phenanthrene derivative (2S*, 3R*)-1-(phenanthrene-2-
carbonyl)piperazine-2,3-dicarboxylic acid). Indeed, in vitro, in contrast to the two other compounds, UBP145
prevented NMDA toxicity only in neurons expressing GluN2D (ie, in cortical but not hippocampal neurons).
Furthermore, in cultured cortical neurons, UBP145 fully prevented the pro-excitotoxic effect of tPA. In vivo, we
showed that UBP145 potently prevented the noxious action of exogenous tPA on excitotoxic damages. Moreover,
in a thrombotic stroke model in mice, administration of UBP145 prevented the deleterious effect of late
thrombolysis by tPA.
Conclusions: In conclusion, tPA exerts noxious effects on neurons by acting on GluN2D-containing NMDAR and
pharmacological antagonists of GluN2D-containing NMDAR could be used to prevent the ability of tPA to promote
neurotoxicity.
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Background
Tissue plasminogen activator (tPA) is a serine protease
initially described to promote vascular fibrinolysis by
converting plasminogen into active plasmin [1]. But tPA
i sn o tj u s tav a s c u l a rp r o t e a s e ,s i n c ei ti sa l s oe x p r e s s e d
by nerve cells and exerts important functions in the
brain parenchyma [2,3]. For instance, during perinatal
development, tPA influences neuronal migration and
synaptic outgrowth [4,5], while in the adult brain, tPA
controls synaptic plasticity [6], long-term potentiation
[7] and long-term depression [8]. In preclinical models
of brain disorders, it has been shown that tPA can dif-
ferentially influence the fate of nerve cells, due to its
pleiotropic actions and targets that include, excitotoxi-
city, apoptosis, neuroinflammation or myelination
[9-13].
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vous system can be explained by several mechanisms.
Among them, there is strong evidence that the direct or
indirect interaction of tPA with the N-methyl-D-aspar-
tate receptor (NMDAR) exerts a positive neuromodula-
tory action [10,14,15]. tPA can thus increase NMDA-
evoked calcium entry, which can be trophic under phy-
siological conditions, or alternatively noxious under
excitotoxic conditions. NMDARs are ion-gated gluta-
mate receptors, mainly described as heterotetrameric
channels composed of two GluN1 subunits and two
GluN2 subunits (in some cases, NMDARs may also con-
tain GluN3 subunits [16,17]). GluN1 and GluN2 subu-
nits exist as isoforms, explaining the varied
electrophysiological properties of NMDARs [18].
NMDARs differentially control neuronal outcome
(trophism versus neurotoxicity) depending on their neu-
ronal localization (synaptic and extrasynaptic) [19,20],
their subunit composition [21] and/or their anchorage
with cytoplasmic or membrane-associated proteins [22].
We have recently demonstrated that the pro-excitotoxic
effects of tPA could be blocked by the co-application of
the weakly-selective GluN2D antagonist, PPDA (phenan-
threne derivative (2S*, 3R*)-1-(phenanthrene-2-carbonyl)
piperazine-2,3-dicarboxylic acid) or silencing of GluN2D
[23]. PPDA is 2- to 5-fold more selective for GluN2C- or
GluN2D-containing NMDARs than for receptors contain-
ing either GluN2A- or GluN2B subunits [24,25]. By
extending the structure-activity analysis around the PPDA
structure, a brominated homolog (UBP145; (2R*,3S*)-1-(9-
bromophenanthrene-3-carbonyl)piperazine-2,3-dicar-
boxylic acid) has been recently produced and character-
ized as being more selective than PPDA, as UBP145
displays a 7- to 17- fold selectivity for GluN2D-containing
NMDARs over GluN2B- or GluN2A-containing NMDARs
[26]. Interestingly, it has also been suggested that meman-
tine, used as Alzheimer’s disease medication, may act as
an antagonist of GluN2D-containing NMDAR [27].
In the present study, we investigated in vitro and in
vivo, whether putative antagonists of GluN2D-contain-
ing NMDAR (memantine, PPDA and UBP145) could
prevent the aggravating effect of tPA on NMDAR-
mediated neurotoxicity. In vitro, we show that UBP145
is more selective than memantine or PPDA, as during
excitotoxic challenges, it acted only on neurons expres-
sing GluN2D. Accordingly, in vivo, UBP145 prevents
the deleterious effects of exogenous tPA against excito-
toxicity and ischemic stroke.
Results
UBP145 selectively prevents tPA-promoted neurotoxicity
mediated by GluN2D-containing NMDA receptor
In a paradigm of rapidly triggered excitotoxicity (expo-
s u r et oah i g hd o s eo fN M D Af o r1h o u ra n d
measurement of neuronal death 24 hours later), we have
previously shown that tPA potentiates neuronal death of
cortical neurons but not of hippocampal neurons. This
differential sensitivity of cortical versus hippocampal
neurons was respectively attributed to the presence and
absence of GluN2D subunits in NMDAR at both the
mRNA and protein levels [23]. Here, we first extended
our previous observations by investigating the sensitivity
to tPA of cortical and hippocampal neurons in vitro, in
a paradigm of slowly triggered excitotoxicity (exposure
to a low dose of NMDA for 24 h). As reported for
rapidly triggered excitotoxicity [23], slowly triggered
excitotoxic cell death was equivalent in both types of
neurons, but tPA (20 μg/ml) increased excitotoxic neu-
ronal death in cortical cultures but not in hippocampal
cultures (see MAP2 immunostaining in Figure 1A and
the corresponding quantification of neuronal death in
Figure 1B; +30%, n = 12, p < 0.05). Our next step was
to compare three pharmacological agents reported to be
more or less selective antagonists of GluN2D, for their
ability to prevent tPA-mediated pro-neurotoxicity: mem-
antine [27,28], PPDA (phenanthrene derivative (2S*,
3R*)-1-(phenanthrene-2-carbonyl)piperazine-2,3-dicar-
boxylic acid) [24]and UBP145 ((2R*,3S*)-1-(9-bromophe-
nan-threne-3-carbonyl)piperazine-2,3-dicarboxylic acid)
[26]. We took advantage of the lack of expression of the
GluN2D in cultured hippocampal neurons when com-
p a r e dt oc o r t i c a ln e u r o n sa n dw ep o s t u l a t e dt h a ta
molecule preferentially targeting the pro-neurotoxicity
effects of tPA: i/should display a dose-dependent inhibi-
tory effect on NMDA-mediated neurotoxicity in cul-
tured cortical neurons, ii/should not influence NMDA-
mediated neurotoxicity in cultured hippocampal neu-
rons; iii/should prevent the aggravating effect of tPA on
NMDA-mediated neurotoxicity in cultured cortical neu-
rons, at a concentration not influencing NMDA alone-
mediated neurotoxicity. The doses of memantine, PPDA
and UBP145 were chosen according to their published
affinity values [24,26,27].
Memantine was tested for its ability to influence
NMDA-mediated neurotoxicity in both cultured cortical
(Figure 2A) and hippocampal neurons (Figure 2B) at 1
and 10 μM. The lowest dose of memantine (1 μM) had
no effect on the extent of NMDA-induced neuronal loss
in cortical (n = 12, p < 0.05, Figure 2A) and hippocam-
pal (n = 12, p < 0.05, Figure 2B) neurons. By contrast,
at the highest dose (10 μM), memantine nearly fully pre-
vented NMDA-mediated neuronal death in both cortical
(n = 12, p < 0.05, Figure 2A) and hippocampal (n = 12,
p < 0.05, Figure 2B) neurons. Since memantine dis-
played the same profile of inhibition of NMDA-
mediated neuronal death in cortical and hippocampal
neurons, memantine did not meet our second selection
criterion.
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Page 2 of 11PPDA (from 0.02 to 2 μM) was tested in the same
paradigm and like memantine, PPDA showed a compar-
able dose-dependent profile of inhibition of NMDA-
mediated neurotoxicity in both cultured cortical (Figure
2C) and hippocampal neurons (Figure 2D). Thus, the
pharmacological profile of PPDA (similar potency to
prevent NMDA-mediated excitotoxicity in cortical and
hippocampal cultures) did not fit with our criteria.
Finally, we tested the more selective GluN2D antago-
nist, UBP145 [26] at 0.2 and 2 μM. Interestingly,
although UBP145 at 2 μM partially reduced NMDA-
mediated neurotoxicity in cultured cortical neurons
(-50%, n = 12, p < 0.05, Figure 3A), it had no effect in
cultured hippocampal neurons (Figure 3B). Moreover, at
0.2 μM, a dose without effect on NMDA-mediated neu-
rotoxicity (Figure 3C), UBP145 completely prevented
tPA-induced potentiation of NMDA-mediated neuro-
toxicity in cultured cortical neurons (n = 12, p < 0.05,
Figure 3C). Consistent with the observation that
UBP145 prevents tPA-induced aggravation of NMDA
toxicity, calcium video-imaging of cortical neurons indi-
c a t e dt h a tt h ec o - i n c u b a t i o no fU B P 1 4 5( 0 . 2μM) com-
pletely abolished the promoting action of tPA (20 μg/
ml) on NMDA-evoked calcium influx (Figure 4B versus
Figure 1 tPA increases NMDA-mediated neurotoxicity in cortical neuronal cultures but not in hippocampal neuronal cultures. Cortical
and hippocampal neurons were exposed to NMDA (10 μM) with or without tPA (20 μg/mL) for 24 hours. (A) Bright field photomicrographs of
cultures stained by peroxidase with a MAP2 immunostaining, scale bar 100 μm. (B) Quantification of neuronal death by LDH release: tPA
increased excitotoxic neuronal death in cortical but not in hippocampal cultures (n = 12; *p < 0.05; NS: not significant).
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Page 3 of 114C, Figure 4E). By itself, UBP145 did not modify
NMDA-evoked calcium influx (Figure 4D). Thus,
UBP145 displays all the criteria of a good candidate to
prevent the pro-neurotoxicity of tPA that occur through
the GluN2D subunit of NMDAR.
In an in vivo excitotoxic challenge, the inhibition of
GluN2D-containing NMDAR can fully prevent the pro-
excitotoxic effect of intravenously administered tPA
Based on our in vitro data, the ability of UBP145 to pre-
vent the pro-neurotoxicity of tPA was tested in mice, in a
model of NMDA-induced excitotoxicity in the cortex. The
dose of tPA was chosen according to our previous works
[10]. For its intravenous administration, the dose of
UBP145 was chosen to respect the molar ratio UBP145/
tPA shown to be efficient in our in vitro studies (Figure 4),
while for its intra-structure administration, the dose of
UBP145 was similar to that of PAI-1 (an inhibitor of tPA)
known to be effective in preventing the noxious effect of
intravenous tPA in the in vivo excitotoxic model [29].
NMDA alone induced a lesion restricted to the cortical
area (n = 6). When injected intravenously, tPA (10 mg/kg)
doubled the NMDA-induced cortical lesion (n = 6, p <
0.01) (Figure 5A,B). In agreement with our in vitro obser-
vations, the cortical co-injection of UBP145 completely
prevented the noxious effect of tPA administration on
NMDA-mediated excitotoxicity (n = 6, p < 0.01) (Figure
5A). In contrast to the neuroprotective effect of UBP145
when administered inside the lesion site, the intravenous
administration of UBP145 (6.67 mg/kg) failed to prevent
the pro-excitotoxic effect of exogenous tPA in our para-
digm of cortical excitotoxicity (Figure 5C,D). Our
Figure 2 Memantine and PPDA protect neurons from NMDA-mediated neurotoxicity in both cortical and hippocampal cultures.
Cortical (A, C) and hippocampal (B, D) neurons were exposed to NMDA (10 μM) with or without memantine (A, B) or PPDA (C, D). At the lowest
doses, memantine (1 μM) and PPDA (0.02 μM) failed to protect both types of neurons, but at the highest doses, memantine (10 μM) and PPDA
(0.2 μM) were able to protect cortical and hippocampal neurons from excitotoxicity (A: n = 12, B: n = 11, C: n = 16, D: n = 9; *p < 0.05; NS: not
significant).
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tive blocker of the deleterious effect of tPA on GluN2D
containing NMDAR, UBP145 does not cross the intact
blood-brain barrier (BBB).
In an in vivo model of thrombotic stroke, the deleterious
effect of late thrombolysis by tPA is reversed by UBP145,
an antagonist of the GluN2D-containing NMDAR
We have developed and fully characterized a model of
thrombotic stroke in mice by injection of thrombin into
the middle cerebral artery, leading to the formation of a
local thrombus [30-32]. In this model, as in the clinical
setting, early thrombolysis by intravenous injection of
tPA is beneficial, while late thrombolysis by tPA is dele-
t e r i o u sa n di n c r e a s e sB B Bl e akage [32]. We thus tested
the effect of intravenous UBP145 (6.67 mg/kg) in this
model of thrombotic stroke coupled or not to a late
thrombolysis by tPA (10 mg/kg). In these experimental
conditions, we have previously demonstrated an opening
of the BBB [32]. Accordingly, the lesion volumes in
mice receiving late thrombolysis by tPA were higher
than the ones measured in mice with no tPA treatment
(Figure 6, +70%, n = 9, p < 0.05). When injected intrave-
nously 4 hours after clot formation, although UBP145
did not influence the ischemic lesion in the absence of
tPA, the deleterious effect of late thrombolysis (tPA iv, 4
hours after clot formation) was completely prevented by
the co-injection of UBP145 (n = 7, p < 0.05).
Discussion
We have previously demonstrated that tPA is pro-exci-
totoxic in cortical neurons but not in hippocampal
Figure 3 UBP145 has no effect on NMDA-mediated neurotoxicity in hippocampal neurons but prevents tPA-induced potentiation of
NMDA-mediated neurotoxicity in cortical neurons. Cortical (A, C) and hippocampal (B) neurons were exposed to NMDA (10 μM) with or
without UBP145 and tPA (20 μg/mL) for 24 hours. Quantification of neuronal death by LDH release in the medium: (A, B) UBP145 2 μM
protected cortical but not hippocampal neurons from neurotoxicity, (C) although UBP145 0.2 μM did not protect cortical neurons from
excitotoxicity, it was able to prevent tPA-induced potentiation of excitotoxicity (n = 12; *p < 0.05; NS: not significant).
Jullienne et al. Molecular Neurodegeneration 2011, 6:68
http://www.molecularneurodegeneration.com/content/6/1/68
Page 5 of 11neurons. We also evidenced by using both pharmaco-
logical and molecular approaches that this discrepancy
could be due to a selective action of tPA on extra-
synaptic NMDAR containing the GluN2D subunit [23].
These observations support the ideas that there are
several subpopulations of NMDAR and that these sub-
populations exert differential and even sometimes
opposite actions (such as trophic versus neurotoxic
effects. These differential actions of NMDAR can be at
least in part attributed to variations in their subunit
composition and/or recruitment of different intracellu-
lar signalling pathways. To date, this idea had been
mainly investigated for GluN2A and GluN2B
[21,33,34], but little is known regarding other GluN2
variants. Thus, further investigating the relative contri-
bution of different NMDAR populations is relevant for
many physiological/pathological situations, including
the ones involving tPA and/or GluN2D, such as learn-
ing/memory processes [35-37], food intake [38], stroke
[3,23], Alzheimer’s disease [39,40] or nociception [41].
We thus sought here to characterize among the cur-
rently available drugs suggested to preferentially act on
GluN2D-containing NMDAR (ie, memantine, PPDA
and UBP145), which one is the more efficient in tar-
geting the potentiating effects of tPA on NMDAR-
mediated neuronal death.
In the United States and Europe, memantine is indi-
cated to treat patients with moderate to severe Alzhei-
mer’s disease. Recently, it has been reported that in the
presence of 1 mM magnesium, memantine becomes 6-8
fold more selective for GluN2C- or GluN2D-containing
receptors over those with either GluN2A or GluN2B
subunits [28]. However, in our hands, memantine was
as efficient in preventing NMDA neurotoxicity in
Figure 4 UBP145 prevents tPA-promoted NMDA-induced Ca
2+ influx in cortical neurons. Two successive 30 second exposures to NMDA
(50 μM) lead to a rapid and reproducible Ca
2+ influx in cultured cortical neurons (A-D; n = 3 independent cultures; n = 150 cells). Cells were
then incubated for 45 minutes with tPA alone (20 μg/mL) or with UBP145 0.2 μM. NMDA exposure was performed again. In contrast to tPA
alone (B, E), when co-incubated with UBP145, tPA did not promote NMDA-induced Ca
2+ influx in cortical neurons (C, E). UBP145 alone at 0.2 μM
did not affect NMDA-induced Ca
2+ influx (D, E). For each condition, illustrative images (during NMDA stimulation before and after treatment) are
provided at the top of calcium recordings (A-D).
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campal) GluN2D.
We then used another weakly-selective GluN2D com-
petitive antagonist, PPDA [24,25] and the more selective
agent, UBP145 [26]. Much lower doses of PPDA than
those of memantine were used, but like memantine,
PPDA displayed a similar potency to prevent NMDA-
mediated excitotoxicity in cortical and hippocampal
cultures. By contrast, we found that low doses of
UBP145 could differentially affect NMDA-induced death
of cortical and hippocampal neurons that respectively
express and do not express GluN2D. UBP145 thus
appears as a sufficiently-selective pharmacological
antagonist of GluN2D as to selectively protect GluN2D-
expressing cortical neurons. At a very low dose -not
influencing the extent of NMDA-induced excitotoxicity-
Figure 5 In vivo, UBP145 can fully prevent the pro-excitotoxic effect of intravenously administered tPA. Cortical injections of NMDA (2.5
nmoles; in 0.33 μl), alone or with UBP145 (0.05 nmoles) were performed in mice using a stereotaxic frame. (A) When UBP145 was co-injected
with NMDA, it prevented tPA-induced potentiation of the excitotoxic lesion (n = 6 per group, **p < 0.01; NS: not significant). (B) When UBP145 was
administered intravenously, it was not able to reduce NMDA-induced excitotoxic lesion (n = 5 per group; NS: not significant). Scale bar: 400 μm
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death. Consistent with this, tPA was unable to increase
NMDA-evoked calcium influx when co-administered
with UBP145. These in vitro data argue again that
GluN2D-containing NMDAR are the critical effectors of
the pro-excitotoxic effects of tPA. From a molecular
point of view, this is in agreement with the demonstra-
tions that neurotoxicity is mediated by extra-synaptic
NMDAR [19] and that GluN2D is exclusively distributed
in extra-synaptic NMDAR [37].
We then used UBP145 in vivo in an attempt to pre-
vent the deleterious action of tPA during excitotoxic
challenges. First, we observed that UBP145 can block
the pro-excitotoxic effect of exogenous tPA (adminis-
tered intravenously) in a model of cortical excitotoxicity.
However, this prevention requires that UBP145 is admi-
nistered in the brain parenchyma, as no effect was
observed for an intravenous injection. This suggests that
in this model that does not induce blood-brain barrier
leakage [29], UBP145 cannot extravasate into the brain
parenchyma. Yet, in a model of thrombotic stroke highly
relevant to the clinical setting [30-32], we found that
UBP145 co-injected intravenously with tPA fully pre-
vented the noxious action of late tPA-mediated throm-
bolysis on the extent of ischemic brain damage. This
strongly suggests that, in conditions of ischemic brain
injury, in which the integrity of the BBB is altered
[30-32], the GluN2D-containing NMDAR antagonist
UBP145, could be used as an adjunct therapy to increase
the therapeutic window of tPA-mediated thrombolysis
that today, is restricted to the first 4.5h after stroke
onset [42].
Conclusion
In conclusion, we provide here strong evidence that tPA
influences neurotoxicity selectively through GluN2D-
containing NMDAR and we provide support for the use
of antagonists like UBP145 in order to selectively pre-
vent the deleterious effects of tPA on NMDAR-mediated
pathological functions.
Methods
Materials
NMDA, memantine and PPDA were purchased from
T o c r i s( B r i s t o l ,U K ) .H u m an recombinant tPA (rtPA;
Actilyse
®) was purchased from Boehringer Ingelheim
(Paris, France). Dulbecco’sm o d i f i e dE a g l e ’sm e d i u m
(DMEM), poly-D-lysine, laminin, glutamine, cytosine b-
D-arabinoside, HEPES-buffered saline solution (HBBSS)
and glycine were purchasedf r o mS i g m a - A l d r i c h( L ’Isle
d’Abeau, France). UBP145 was produced as previously
described [12].
Neuronal cultures
Neuronal cultures were prepared from Swiss mouse
embryos (embryonic day 15-16) as described earlier
[23]. Cortices or hippocampi were dissected and disso-
ciated in DMEM, and plated, respectively, on 24- and
48-well plates previously coated with poly-D-lysine (0.1
mg/ml) and laminin (0.02 mg/ml). Cells were cultured
in DMEM supplemented with 5% foetal bovine serum,
5% horse serum (both from Invitrogen, Cergy Pontoise,
France) and 2 mM glutamine. Cultures were maintained
at 37°C in a humidified 5% CO2 atmosphere. To inhibit
glial proliferation, cytosine ß-D-arabinoside (10 μM) was
added after 3 or 1 day(s) in vitro (DIV) in cortical and
hippocampal cultures, respectively.
Excitotoxic neuronal death
Excitotoxicity was induced at 12-13 DIV by exposure to
NMDA (10 μM) in serum-free DMEM supplemented
with 10 μM of glycine for 24 hours. NMDA was applied
alone or together with rtPA (20 μg/ml) and/or antago-
nists. After 24 hours, neuronal death was estimated by
Microtubule-associated protein 2 (MAP2) immunostain-
ing and quantified by measurement of the activity of lac-
tate dehydrogenase (LDH) released from damaged cells
into the bathing medium with a cytotoxicity detection
kit (Roche Diagnostics, Mannheim, Germany). The LDH
level corresponding to the maximal neuronal death was
Figure 6 UBP145 reverses the deleterious effect of late
thrombolysis by tPA in an in vivo model of thrombotic stroke.
Thrombotic stroke was induced in mice by injection of thrombin (1
UI.) into the middle cerebral artery. Late intravenous thrombolysis
by tPA (10 mg/kg) alone or in combination with UBP145 (6.67 mg/
kg) was performed 4 hours after MCA occlusion. The co-
administration of UBP145 with tPA prevented the deleterious effects
of late thrombolysis with tPA (*p < 0.05). Representative thionine-
stained sections are shown for each condition.
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NMDA. Background LDH levels were determined in sis-
ter cultures subjected to control washes. Experimental
values were measured after subtracting LDHmin and
then normalized to LDHmax-LDHmin to express the
results in percentage of neuronal death.
Calcium videomicroscopy
Experiments were performed at room temperature on
t h es t a g eo faN i k o nE c l i p s ei n v e r t e dm i c r o s c o p e
equipped with a 75 W Xenon lamp and a Nikon 40x,
1.3 numerical aperture epifluorescence oil immersion
objective. Cell cultures were transferred into a serum
free medium (HBBSS) and loaded with fura-2/AM 10
μM (Invitrogen) for 45 minutes at 37°C. Neurons were
washed and NMDA treatment (1 mL at 50 μM) was
applied using a peristaltic pump (2 mL/minute).
UBP145 (0.2 μM) and/or tPA (20 μg/mL) were directly
applied in the medium and incubated for 45 minutes.
Fura-2 (excitation: 340, 380 nm, emission: 510 nm) ratio
images were acquired with a CCD camera (Princeton
Instrument, Trenton, New Jersey), and digitized (256 ×
512 pixels) using Metafluor 4.11 software (Universal
Imaging Corporation, Chester, Pennsylvania).
Animals
Experiments were performed on male Swiss mice (32 ±
3 g, produced and provided by our local animal facil-
ities, France) in accordance with European communities
Council (Directives of November 24, 1986 (86/609/
EEC)) and French Legislation (act no. 87-848, Ministère
de l’Agriculture et de la Forêt) on Animal Experimenta-
tion and were approved by the local ethical committee.
Mice were deeply anesthetized with isoflurane 5% and
maintained under anesthesia with 2% isoflurane in a
70%/30% gas mixture (N2O/O2) during surgery. The
rectal temperature was maintained at 37 ± 0.5°C
throughout the surgical procedure using a feedback-
regulated heating system.
In vivo excitotoxic lesions
A cortical unilateral injection (coordinates: 0.5 mm pos-
terior, 3.0 mm lateral, -0.8 mm ventral to the bregma;
stereotaxic atlas G. Paxinos & K.B.J. Franklin) of NMDA
(2.5 nmoles; in 0.33 μl), co-injected or not with UBP145
(0.05 nmoles) was performed after placing the animals
in a stereotaxic frame. Solutions were injected by the
use of a micropipette made with hematologic micropip-
ettes (calibrated at 15 mm/μl; assistant ref 555/5; Hecht,
Sondheim-Rhoen, Germany). The micropipette was
removed 3 minutes later. After the excitotoxic lesion, a
200 μl bolus intravenous injection of rtPA (10 mg/kg)
or saline was performed through a catheter previously
inserted into the tail vein.
In a second set of experiments, UBP145 was tested for
its ability to cross the blood-brain barrier. In this case,
cortical excitotoxic lesions were performed with NMDA,
as above, followed by tail vein injections of rtPA alone
(10 mg/kg) or in association with UBP145 (pH 7.4; 6.67
mg/kg).
A f t e r2 4h o u r s ,m i c ew e r ed e e p l ya n e s t h e t i z e da n d
then transcardially perfused with cold heparinized sal-
ine (15 ml) followed by 150 ml of fixative (phosphate
buffer 0.1 M. pH 7.4 containing 2% paraformaldehyde
and 0.2% picric acid). Brains were post-fixed (18
hours; 4°C) and cryoprotected (sucrose 20% in phos-
phate buffer; 24 hours; 4°C) before freezing in Tissue-
Tek (Miles Scientific, Naperville, IL, USA). Cryomi-
crotome-cut transversal sections (20 μm) were col-
lected on poly-lysine slides and stained with Fluoro-
Jade C [43]. Subsequently, images were captured with
a Leica DM6000 microscope-coupled to a coolsnap
camera. Cortical lesion surfaces were determined
using sections covering 500 μm anterior and posterior
to the injection site by using an image analysis system
(MetaVue software, Molecular Devices, Downingtown,
PA, USA).
Thrombotic model of stroke and thrombolysis
The same male Swiss mice were placed in a stereotaxic
frame and maintained undera n e s t h e s i a .A f t e ras k i n
incision between the right eye and ear, the master
muscle was excised and a small craniotomy (Ø 1 mm)
was performed on the parietal bone in order to expose
the right middle cerebral artery (MCA). Then, 1 μlo f
murine a-thrombine (1UI. Sigma Aldrich) was injected
in the MCA using hematological micropipettes to acti-
vate the coagulation cascade as previously described
[30]. To induce thrombolysis, rtPA (10 mg/kg) was
injected (200 μl, i.v., 10% bolus and 90% infusion over
40 minutes), 4 hours after MCA occlusion, with or
without UBP145 (6.67 mg/kg). Finally, control groups
received the same volume of saline with or without
UBP145. Cerebral blood velocity was measured by
laser-Doppler flowmetry using an optic fiber probe
(Oxford Optronix, UK) placed on the skull in the
MCA territory. After 24 hours, brains were collected
and frozen in isopentane. Then, coronal brain sections
(20 μm) were stained with thionine and analyzed with
an image analysis software (Image J).
Statistical analyses
The results are expressed as the mean ± S.E.M. Statisti-
cal analyses were performed by the Kruskall-Wallis’ test,
followed by post hoc comparisons, with the Mann-Whit-
ney’s test. For calcium videomicroscopy, statistical ana-
lyses were performed using Student test. Statistical
significances were concluded for p < 0.05.
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